Harmony Biosciences Holdings, Inc. (HRMY) stock
HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3039% below fair value
$33.11+0.10 (+0.30%)
Close on Nov 18, 2026Market cap $1.93BP/E 10.7Yield –
Harmony Biosciences price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Harmony Biosciences's price to book ratio was 2.0× on Nov 11, 2026, against 2.4× a year earlier. Over the last 5 years it ranged from 1.9× to 16.4×, with a median of 3.7×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.0× | −0.6 |
| 2025 | Dec 31, 2025 | 2.6× | −0.7 |
| 2024 | Dec 31, 2024 | 3.3× | −0.6 |
| 2023 | Dec 29, 2023 | 3.9× | −5.6 |
| 2022 | Dec 30, 2022 | 9.5× | −6.9 |
| 2021 | Dec 31, 2021 | 16.4× | −5.4 |
| 2020 | Dec 31, 2020 | 21.8× | – |
See a number that looks wrong?